Erdafitinib 4 Mg Tablets

Introduction

Erdafitinib 4 mg Tablets are prescription targeted anticancer medicines used for the treatment of certain locally advanced or metastatic urothelial carcinoma (bladder and urinary tract cancer) with susceptible FGFR3 genetic alterations. Erdafitinib is a selective fibroblast growth factor receptor (FGFR) inhibitor that blocks abnormal FGFR signaling involved in cancer-cell growth and survival. Treatment should be initiated and monitored by an experienced oncologist.

Composition

• 
  Active Ingredient: Erdafitinib
  


• 
  Strength: 4 mg
  


• 
  Dosage Form: Film-Coated Tablet
  


• 
  Therapeutic Class: FGFR Tyrosine Kinase Inhibitor / Targeted Anticancer Agent
  

Uses

Treatment of eligible patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations.

Used in appropriate patients following prior systemic therapy, according to the applicable approved indication.

Requires confirmation of the relevant FGFR3 alteration using validated molecular diagnostic testing.

Helps inhibit abnormal FGFR signaling and slow cancer-cell growth and progression.

Dosage

Take Erdafitinib 4 mg exactly as prescribed by your oncologist. The usual recommended adult starting dose is 8 mg once daily, with possible adjustment to 9 mg once daily depending on phosphate levels and tolerability.

The 4 mg strength may be used as part of the prescribed dose or for dose adjustments. An 8 mg dose generally requires two 4 mg tablets once daily.

Erdafitinib may be taken with or without food. Swallow the tablets whole with water. Do not crush or chew the tablets.

Precautions

• 
  Use only under the supervision of a qualified oncologist.
  


• 
  Erdafitinib may cause hyperphosphatemia, eye disorders, dry mouth, diarrhea, skin and nail changes, and liver enzyme abnormalities.
  


• 
  Serious ocular effects, including retinal pigment epithelial detachment, can occur and require regular ophthalmologic monitoring.
  


• 
  Regular monitoring of serum phosphate, liver function, kidney function, and eye health is recommended.
  


• 
  Inform your doctor if you have existing eye disease, kidney disease, liver disease, or abnormal phosphate levels.
  


• 
  Report blurred vision, visual-field changes, eye discomfort, severe skin reactions, or significant gastrointestinal symptoms promptly.
  


• 
  Tell your healthcare provider about all prescription medicines, over-the-counter drugs, vitamins, and herbal supplements because drug interactions may occur.
  


• 
  Pregnancy should be avoided during treatment because erdafitinib may cause fetal harm.
  


• 
  Do not alter or discontinue treatment without medical advice.
  

Storage

Store at room temperature in a cool, dry place away from direct sunlight, excessive heat, and moisture. Keep the tablets in their original packaging and out of reach of children.

Conclusion

Erdafitinib 4 mg Tablets are a targeted FGFR inhibitor used for eligible patients with FGFR3-altered locally advanced or metastatic urothelial carcinoma. The 4 mg strength provides flexibility for the usual 8 mg once-daily starting regimen and subsequent dose adjustments. Molecular testing and regular monitoring of phosphate levels and ocular health are important during treatment.